Inquiry Basket
Loading ......
Filter By Product Search for
Trazodone
Trazodone Full Name
Trazodone
Trazodone Introduction
Trazodone is a multifunctional antidepressant whose therapeutic profile extends beyond serotonin reuptake inhibition, making it a valuable option for patients who experience depression accompanied by insomnia, anxiety, or disrupted sleep architecture. While its primary pharmacological targets include the serotonin transporter (SLC6A4) and serotonin 5-HT2A/5-HT2C receptors (HTR2A/HTR2C), increasing evidence suggests that its biological effects also involve molecular pathways associated with neuroplasticity and circadian rhythm regulation. Chronic trazodone treatment has been shown to increase the expression of BDNF (Brain-Derived Neurotrophic Factor) together with core circadian clock genes including BMAL1 (ARNTL), PER1, and PER2 in brain regions critical for emotional regulation, such as the hippocampus, amygdala, and cerebral cortex. These findings indicate that trazodone may promote recovery from depressive symptoms not only by enhancing serotonergic neurotransmission but also by restoring neuronal resilience and normalizing biological rhythms, mechanisms that are increasingly recognized as essential for sustained antidepressant efficacy.
Understanding the molecular targets associated with trazodone is particularly important because patient response and tolerability vary considerably due to pharmacogenetic differences. Among the best-characterized genes, CYP2D6 plays a central role in trazodone metabolism by influencing the formation and clearance of its active metabolite, m-chlorophenylpiperazine (mCPP). Individuals with reduced CYP2D6 activity or poor metabolizer phenotypes may experience higher circulating concentrations of pharmacologically active metabolites and an increased risk of adverse drug reactions. Recent pharmacogenetic studies have further strengthened the association between decreased CYP2D6 function and a substantially elevated likelihood of treatment-related side effects, supporting the growing clinical value of genotype-guided prescribing. Additional genes, including SLC6A4 and HTR2A, have also been investigated for their influence on antidepressant response and adverse effects. Although current evidence does not yet support routine clinical testing for all serotonergic receptor variants, these pharmacogenomic markers continue to improve our understanding of interindividual variability and may contribute to future precision psychiatry strategies.
Beyond its established role in major depressive disorder, trazodone has attracted increasing attention in research on neurodevelopmental and neurodegenerative diseases because of its broader effects on cellular metabolism. Experimental studies have demonstrated that trazodone can influence cholesterol biosynthesis by affecting the SREBP (Sterol Regulatory Element-Binding Protein) signaling pathway, leading to altered sterol homeostasis and elevated 7-dehydrocholesterol (7-DHC) levels under specific experimental conditions. These findings are particularly relevant for disorders involving impaired cholesterol metabolism, such as Smith-Lemli-Opitz syndrome (SLOS), where disturbances in lipid biosynthesis may exacerbate neurological dysfunction. At the same time, the observed regulation of BDNF expression, circadian clock genes, serotonergic signaling, and metabolic pathways highlights the complexity of trazodone's mechanism of action. Ongoing research continues to identify biomarkers that may predict therapeutic response, treatment resistance, and safety, providing a stronger molecular foundation for individualized antidepressant therapy and expanding the potential applications of trazodone in neuroscience and precision medicine.
Alternate Names for Trazodone
Trazodone; Desyrel; Oleptro; Beneficat; Deprax; Desirel; Molipaxin; Thombran; Trazorel; Trialodine; Trittico; Mesyrel;
Loading ......
